Weber J S, Aparicio A
Department of Medicine/Oncology, University of Southern California, Keck School of Medicine, Los Angeles, California 90089, USA.
Curr Opin Oncol. 2001 Mar;13(2):124-8. doi: 10.1097/00001622-200103000-00007.
In the past decade, the discovery of tumor antigens recognized by T cells has revolutionized the tumor vaccine field. The appreciation that peptides are bound to and restricted by major histocompatibility class I and II molecules for immune recognition has encouraged a number of early-phase clinical trials of peptide vaccines. I summarize herein the rationale for and the results of a number of clinical trials of peptide vaccines for melanoma, suggesting that immune and clinical responses can be seen in those with metastatic and resected disease using a variety of surrogate assays. The challenge for the future is to correlate the results of immunologic assays with clinical benefit in patients with advanced cancer.
在过去十年中，T细胞识别的肿瘤抗原的发现彻底改变了肿瘤疫苗领域。人们认识到肽与主要组织相容性复合体I类和II类分子结合并受其限制以进行免疫识别，这推动了多项肽疫苗的早期临床试验。在此，我总结了一些针对黑色素瘤的肽疫苗临床试验的基本原理和结果，表明使用各种替代检测方法，在患有转移性疾病和已切除疾病的患者中可以观察到免疫反应和临床反应。未来的挑战是将免疫检测结果与晚期癌症患者的临床获益相关联。
